FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 ac
ERBB2 kinase domain mutations that were reported in solid cancers were shown along with their structural position and IC50 values against lapatinib and AEE 788. IC50 values were calculated based on Fi
Effective therapy for malignant melanoma, the leading cause of death from skin cancer, remains an area of significant unmet need in oncology. Increased expression of PKCε in advanced metastatic melano
The mutated residues in the yeast strains are presented in Table 2 for the Plasmodium-like mutants (PF) and in Table 3 for the human-like mutants (HS). Their location in the sequence and the structure
Several reports have demonstrated a role for aberrant NOTCH signaling in melanoma genesis and progression, prompting us to explore if targeting this pathway is a valid therapeutic approach against mel
